Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
4.310
-0.150 (-3.36%)
At close: Feb 27, 2026, 4:00 PM EST
4.345
+0.035 (0.80%)
After-hours: Feb 27, 2026, 7:59 PM EST
Altimmune Market Cap
Altimmune has a market cap or net worth of $539.75 million as of February 27, 2026. Its market cap has increased by 22.00% in one year.
Market Cap
539.75M
Enterprise Value
344.88M
1-Year Change
22.00%
Ranking
Category
Stock Price
$4.31
Market Cap Chart
Since October 6, 2005, Altimmune's market cap has increased from $81.50M to $539.75M, an increase of 562.27%. That is a compound annual growth rate of 9.71%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 27, 2026 | 449.30M | 19.37% |
| Dec 31, 2025 | 376.40M | -26.60% |
| Dec 31, 2024 | 512.80M | -15.16% |
| Dec 29, 2023 | 604.40M | -25.26% |
| Dec 30, 2022 | 808.70M | 122.17% |
| Dec 31, 2021 | 364.00M | -2.41% |
| Dec 31, 2020 | 373.00M | 1,186.21% |
| Dec 31, 2019 | 29.00M | 61.11% |
| Dec 31, 2018 | 18.00M | -42.12% |
| Dec 29, 2017 | 31.10M | -85.66% |
| Dec 30, 2016 | 216.90M | 77.06% |
| Dec 31, 2015 | 122.50M | 6.80% |
| Dec 31, 2014 | 114.70M | 17.88% |
| Dec 31, 2013 | 97.30M | 79.52% |
| Dec 31, 2012 | 54.20M | -11.58% |
| Dec 30, 2011 | 61.30M | -64.57% |
| Dec 31, 2010 | 173.00M | 210.59% |
| Dec 31, 2009 | 55.70M | -6.39% |
| Dec 31, 2008 | 59.50M | -31.77% |
| Dec 31, 2007 | 87.20M | 1.04% |
| Dec 29, 2006 | 86.30M | 4.10% |
| Dec 30, 2005 | 82.90M | 1.72% |
View and export this data all the way back to 2005.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Ocugen | 614.79M |
| MeiraGTx Holdings | 614.15M |
| LB Pharmaceuticals | 603.13M |
| Allogene Therapeutics | 602.28M |
| Neumora Therapeutics | 599.03M |
| Design Therapeutics | 598.97M |
| Alto Neuroscience | 585.60M |
| Fulcrum Therapeutics | 580.75M |